Shire
Shire to close Hampshire base and relocate jobs, say reports
April 27, 2016Manufacturing and Production, Research and Development Jobs, Shire, close, factory, hampshire, loss, relocate
Shire is set to cease operations at its site in Basingstoke, Hampshire, by the end of next year and relocate …
Shire announces new $400 million biologics plant and 400 new jobs in Ireland
April 18, 2016Manufacturing and Production, Sales and Marketing IDA, Ireland, Shire, investment, meath, shire pharmaceuticals
Shire Pharmaceuticals has announced the expansion of its Irish operations with a new $400 million biologics plant set to deliver …
Shire reassures Baxalta acquisition on track in the aftermath of Pfizer-Allergan breakup
April 7, 2016Business Services, Sales and Marketing AbbVie, Allergan, Baxalta, Deals, Financial, Merger & Acquisition, Pfizer, Shire
Ireland-headquartered Shire Plc (LSE: SHP) has reassured its $32-billion merger deal with US-based Baxlata (NYSE: BXLT) remains on track in …
Shire wins v Allergan in Lialda patent case
March 30, 2016Research and Development, Sales and Marketing Allergan, Shire, lialda
A US district court has ruled that Shire’s patent for ulcerative colitis drug Lialda is valid through 2020, leaving Allergan …
Shire launches long-acting ADHD drug in UK
March 9, 2016Sales and Marketing ADHD, Shire
Shire has launched its long-acting ADHD drug Intuniv (guanfacine) in the UK, for children and adolescents aged 6-17. The treatment …
FDA to decide on Shire blockbuster hopeful
February 8, 2016Manufacturing and Production, Research and Development, Sales and Marketing Shire, dry eye disease, lifitegrast
The FDA has accepted Shire’s new drug application (NDA) for its dry eye disease drug lifitegrast, putting the treatment on …
Shire tries again with lifitegrast dry eye FDA application
January 25, 2016Manufacturing and Production, Sales and Marketing FDA, Shire, dry eye disease, lifitegrast
Shire has resubmitted its New Drug Application (NDA) to the US FDA for its rejected dry eye syndrome drug lifitegrast. …
Shire and Baxalta reach $32 billion merger agreement
January 11, 2016Manufacturing and Production, Sales and Marketing Baxalta, Shire, mergers, mergers and acquisitions
One of the industry’s longest-running M&A sagas has finally reached a conclusion, with Shire and Baxalta announcing a $32 billion …
Reports: $32bn Shire takeover of Baxalta close to done deal
January 4, 2016Sales and Marketing Baxalta, Shire, acquisition, merger
The deal may have failed to get over the line in 2015, but reports suggest the mega merger is to …
Shire moves to seal Baxalta deal with improved offer
December 22, 2015Research and Development, Sales and Marketing Baxalta, Flemming Ornskov, Shire
Shire is set to sweeten its $30 billion bid for Baxalta by offering 40% of the total, or $12 billion, …
New treatments to boost dry eye drug market – if approved
November 5, 2015Sales and Marketing Allergan, Ikervis, Restasis, Shire, cyclosporine, dry eye disease, dry eye syndrome, lifitegrast
The global market for treatments for dry eye syndrome will double in value to an estimated $4.6 billion by 2024, …
Shire to acquire Dyax in $5.9 billion deal
November 2, 2015Manufacturing and Production, Research and Development, Sales and Marketing Dyax, M&A, MA, R&D, Shire, hereditary angioedema, rare disease
Shire has struck a deal to acquire the biotech firm Dyax for $5.9 billion, in order to acquire exclusive rights …
New Phase III data puts Shire’s lifitegrast back on track for 2016 launch
October 27, 2015Research and Development Shire, dry eye disease, lifitegrast
Shire shares rose 6% today as the company reported new positive Phase III trial data for lifitegrast in the treatment …
Shire reports 7% product sales growth, continues Baxalta pursuit
October 23, 2015Sales and Marketing Baxalta, Shire
Shire has exceeded market expectations as it reported an 11% rise in Q3 earnings on Friday, driven by product sales, …
Shire’s dry eye treatment gets a no – for now
October 19, 2015Sales and Marketing Complete Response Letter, FDA, Flemming Ornskov, Shire, dry eye disease, lifitegrast
Shire has seen an application for its dry eye treatment lifitegrast rejected by the US regulator. The FDA says it …
Latest content
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour
